ImpediMed（IPDQ.F）株式概要医療技術企業であるImpediMed Limitedは、生体インピーダンス分光法（BIS）技術の医療機器を製造し、欧米で販売している。 詳細IPDQ.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長2/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より93.7%で取引されている 収益は年間29.35%増加すると予測されています リスク分析意味のある時価総額がありません ( $10M )株式の流動性は非常に低い 過去1年間で株主の希薄化が進んだ 現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るIPDQ.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.005979.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-29m52m2016201920222025202620282031Revenue AU$51.5mEarnings AU$6.7mAdvancedSet Fair ValueView all narrativesImpediMed Limited 競合他社IceCure MedicalSymbol: NasdaqCM:ICCMMarket cap: US$15.2mTrinity BiotechSymbol: NasdaqGS:TRIBMarket cap: US$11.7mPicard MedicalSymbol: NYSEAM:PMIMarket cap: US$16.8mSintx TechnologiesSymbol: NasdaqCM:SINTMarket cap: US$9.1m価格と性能株価の高値、安値、推移の概要ImpediMed過去の株価現在の株価AU$0.005952週高値AU$0.05152週安値AU$0.0045ベータ1.11ヶ月の変化-15.31%3ヶ月変化n/a1年変化-81.24%3年間の変化-94.73%5年間の変化-92.26%IPOからの変化-98.62%最新ニュースお知らせ • May 06+ 1 more updateImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million.ImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,020,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listingお知らせ • Apr 08+ 1 more updateImpediMed Limited Announces Chief Executive Officer ChangesImpediMed Limited announced the appointment of Erik Anderson as Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026. Anderson's appointment comes as ImpediMed's business gains momentum with its Breast Cancer Related Lymphedema (BCRL) business. The Board determined that the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson's appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation. Anderson brings to ImpediMed extensive commercial leadership experience in the US medical technology sector. Most recently, he served as President of the Breast and Skeletal Health Division at Hologic Inc. . During his tenure at Hologic, he led a large, multi-franchise commercial organization and grew one of the company's largest business units—a $1.6+ billion global franchise. He also brings deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed's growth priorities in BCRL, body composition, and heart health. With this experience, Anderson is well-positioned to lead ImpediMed's next phase of growth, expanding sales and distribution across U.S. health systems. Bains will continue in an advisory role through June 30, 2026, to support a smooth leadership transition.お知らせ • Jan 27ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Oct 24ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025お知らせ • Sep 19ImpediMed Limited, Annual General Meeting, Nov 18, 2025ImpediMed Limited, Annual General Meeting, Nov 18, 2025.お知らせ • Jul 16ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025最新情報をもっと見るRecent updatesお知らせ • May 06+ 1 more updateImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million.ImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,020,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listingお知らせ • Apr 08+ 1 more updateImpediMed Limited Announces Chief Executive Officer ChangesImpediMed Limited announced the appointment of Erik Anderson as Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026. Anderson's appointment comes as ImpediMed's business gains momentum with its Breast Cancer Related Lymphedema (BCRL) business. The Board determined that the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson's appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation. Anderson brings to ImpediMed extensive commercial leadership experience in the US medical technology sector. Most recently, he served as President of the Breast and Skeletal Health Division at Hologic Inc. . During his tenure at Hologic, he led a large, multi-franchise commercial organization and grew one of the company's largest business units—a $1.6+ billion global franchise. He also brings deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed's growth priorities in BCRL, body composition, and heart health. With this experience, Anderson is well-positioned to lead ImpediMed's next phase of growth, expanding sales and distribution across U.S. health systems. Bains will continue in an advisory role through June 30, 2026, to support a smooth leadership transition.お知らせ • Jan 27ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Oct 24ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025お知らせ • Sep 19ImpediMed Limited, Annual General Meeting, Nov 18, 2025ImpediMed Limited, Annual General Meeting, Nov 18, 2025.お知らせ • Jul 16ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025お知らせ • Apr 17ImpediMed Limited to Report Q3, 2025 Results on Apr 30, 2025ImpediMed Limited announced that they will report Q3, 2025 results on Apr 30, 2025お知らせ • Jan 28ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025ImpediMed Limited announced that they will report Q2, 2025 results on Jan 31, 2025お知らせ • Oct 15ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024ImpediMed Limited announced that they will report Q1, 2025 results on Oct 22, 2024お知らせ • Sep 27ImpediMed Limited, Annual General Meeting, Nov 19, 2024ImpediMed Limited, Annual General Meeting, Nov 19, 2024.お知らせ • Aug 23ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024ImpediMed Limited announced that they will report fiscal year 2024 results Pre-Market on Aug 29, 2024お知らせ • Jul 22+ 3 more updatesImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basisAs announced in November 2023, Dr. Parmjot Bains, CEO and Managing Director commenced in their roles in an interim capacity. The Board of ImpediMed Limited confirmed the appointment of Dr. Bains as Chief Executive Officer on an ongoing basis. In the 6-month period in their interim roles, Dr. Bains has implemented a number of significant changes across the business to ensure the Company is in the best position to achieve growth and profitability and ensure all patients at risk of cancer related lymphedema can access ImpediMed's unique technology.お知らせ • Jun 08ImpediMed Limited Appoints Fiona Bones as A Non-Executive DirectorThe Board of ImpediMed Limited announced the appointment of Ms Fiona Bones as a non-Executive Director of the Company, effective 07 June 2024. Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones is a Fellow of the Association of Chartered Certified Accountants, UK and Ireland and brings global experience in finance, corporate governance, and systems transformation.お知らせ • Apr 20ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024ImpediMed Limited announced that they will report Q3, 2024 results on Apr 30, 2024お知らせ • Apr 11ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual MeetingImpediMed announced that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on April 12, 2024. The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period. The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure. Lymphedema, a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk. ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with US payors now providing coverage for over 140 million covered lives. The PREVENT trial is a pivotal study and the largest randomized controlled trial to assess lymphedema prevention. The study enrolled 1,200 patients across 10 trial sites in the US and Australia, involving 13 hospitals, including Vanderbilt University, Mayo Clinic and MD Anderson. The trial was conducted over six and a half years and patients were followed for up to three years, with the primary aim to determine if early intervention in patients with subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy results in a lower rate of lymphedema progression versus the rate when tape measure is used for subclinical detection. The manuscript is published in Lymphatic Research and Biology. The results of the trial demonstrated that patients with early detection with L-Dex™ technology and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years.お知らせ • Jan 23ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024ImpediMed Limited announced that they will report first half, 2024 results on Feb 27, 2024お知らせ • Nov 20+ 2 more updatesImpediMed Limited Announces CFO ChangesImpediMed Limited announced leadership and Board changes to drive growth and manage costs. When elected, the Board announced a review of ImpediMed's strategy to ensure it was maximising the potential opportunities to transition to a high growth and profitable business. To date, the Board has considered the Company's operational readiness, approach to execution and cost structure. The review identified a very capable core management team, a distinctive product portfolio and an undeniable opportunity. However, more is needed to deliver robust execution and control costs. Given these challenges and the strong endorsement for change from ImpediMed shareholders at the recent General Meeting, the Board has determined that action now is appropriate. Tim Cruickshank has stepped down as CFO and the Board is discussing transition arrangements with him. Chair McGregor Grant assumes the responsibilities of CFO effective immediately, in an interim capacity and will be an Executive Chairman. The Chair, McGregor Grant will work closely with Dr. Bains as CFO, with a clear focus on managing costs. managing costs. For the last 12 years Mr. Grant was CFO and company Secretary of Nanosonics Limited. As well as leading financial strategy, Mr. Grant played a key role in developing and implementing corporate strategy. He was also responsible for operational functions including IT, legal and facilities management. During Mr. Grant's tenure at Nanosonics revenue grew from $2 million to $166 million. Together, Dr. Bains and Mr. Grant have extensive strategic, sales & marketing, financial and operational experience in high growth MedTech/healthcare businesses and will ensure stability and continuity of the business' operations. The Board recognises the significant talent within the senior management team, and Dr. Bains and Mr. Grant look forward to working closely with them to ensure the entire ImpediMed team remains focused on execution. Dr. Bains and Mr. Grant will also work closely with the management team to more deeply examine the Company's strategic and operational plans and its cost base to maximise the commercial opportunity and deliver value to its shareholders. Dr. Bains and Mr. Grant have been appointed to their roles in an interim capacity, which is expected to be in place for a period of up to six months while they assess the requirements of the business.お知らせ • Oct 24ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023ImpediMed Limited announced that they will report Q1, 2024 results on Oct 31, 2023お知らせ • Oct 12ImpediMed Limited, Annual General Meeting, Nov 30, 2023ImpediMed Limited, Annual General Meeting, Nov 30, 2023, at 10:01 E. Australia Standard Time.お知らせ • Sep 27ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical OfficerImpediMed Limited announced the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023. Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry. Dr. Chen's previous leadership and experience: Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care. Chief of Breast Surgery, University of California Davis Medical Center. Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California. Past President, American Society of Breast Surgeons (ASBrS). Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics. Over 70 publications and 5,000 citations. The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®). Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons. Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business.お知らせ • Jul 17ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023ImpediMed Limited announced that they will report Q4, 2023 results on Jul 24, 2023お知らせ • Jul 06ImpediMed Limited Appoints Daniel Sharp as DirectorImpediMed Limited appointed Mr. Daniel Sharp as director, date of appointment is July 1, 2023.お知らせ • Jan 24ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023ImpediMed Limited announced that they will report Q2, 2023 results on Jan 30, 2023株主還元IPDQ.FUS Medical EquipmentUS 市場7D0%-1.1%1.4%1Y-81.2%-20.7%25.7%株主還元を見る業界別リターン: IPDQ.F過去 1 年間で-20.7 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: IPDQ.Fは、過去 1 年間で25.7 % のリターンを上げたUS市場を下回りました。価格変動Is IPDQ.F's price volatile compared to industry and market?IPDQ.F volatilityIPDQ.F Average Weekly Movementn/aMedical Equipment Industry Average Movement8.8%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: IPDQ.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のIPDQ.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト199977Erik Andersonwww.impedimed.com医療技術会社であるImpediMed Limitedは、生体インピーダンス分光法(BIS)技術の医療機器を米国と欧州で製造・販売している。同社は、リンパ浮腫の臨床評価と体液状態と組織組成のスナップショットを提供するための非侵襲的BIS装置であるSOZO、リンパ浮腫のためのL-Dex分析、ポイント・オブ・カー体組成分析であるBodyComp分析、ポイント・オブ・ケア心不全体液評価のためのHF-Dex分析を提供している。また、健康な人の体組成を分析するシングルチャンネル4極BIS装置SFB7や、動物用アプリケーション向けに体液状態と組織組成を測定するシングルチャンネル4極（BIS）装置ImpediVETも提供している。同社は1999年に設立され、カリフォルニア州カールスバッドに本社を置いている。もっと見るImpediMed Limited 基礎のまとめImpediMed の収益と売上を時価総額と比較するとどうか。IPDQ.F 基礎統計学時価総額US$9.82m収益（TTM）-US$17.07m売上高(TTM)US$9.97m1.0xP/Sレシオ-0.6xPER（株価収益率IPDQ.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計IPDQ.F 損益計算書（TTM）収益AU$14.23m売上原価AU$1.97m売上総利益AU$12.26mその他の費用AU$36.63m収益-AU$24.37m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.01グロス・マージン86.14%純利益率-171.25%有利子負債／自己資本比率231.3%IPDQ.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/22 16:32終値2026/06/01 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ImpediMed Limited 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関James WilliamsonBell PotterMartyn JacobsBell PotterShane StoreyCanaccord Genuity2 その他のアナリストを表示
お知らせ • May 06+ 1 more updateImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million.ImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,020,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 08+ 1 more updateImpediMed Limited Announces Chief Executive Officer ChangesImpediMed Limited announced the appointment of Erik Anderson as Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026. Anderson's appointment comes as ImpediMed's business gains momentum with its Breast Cancer Related Lymphedema (BCRL) business. The Board determined that the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson's appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation. Anderson brings to ImpediMed extensive commercial leadership experience in the US medical technology sector. Most recently, he served as President of the Breast and Skeletal Health Division at Hologic Inc. . During his tenure at Hologic, he led a large, multi-franchise commercial organization and grew one of the company's largest business units—a $1.6+ billion global franchise. He also brings deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed's growth priorities in BCRL, body composition, and heart health. With this experience, Anderson is well-positioned to lead ImpediMed's next phase of growth, expanding sales and distribution across U.S. health systems. Bains will continue in an advisory role through June 30, 2026, to support a smooth leadership transition.
お知らせ • Jan 27ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Oct 24ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025
お知らせ • Sep 19ImpediMed Limited, Annual General Meeting, Nov 18, 2025ImpediMed Limited, Annual General Meeting, Nov 18, 2025.
お知らせ • Jul 16ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025
お知らせ • May 06+ 1 more updateImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million.ImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,020,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 08+ 1 more updateImpediMed Limited Announces Chief Executive Officer ChangesImpediMed Limited announced the appointment of Erik Anderson as Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026. Anderson's appointment comes as ImpediMed's business gains momentum with its Breast Cancer Related Lymphedema (BCRL) business. The Board determined that the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson's appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation. Anderson brings to ImpediMed extensive commercial leadership experience in the US medical technology sector. Most recently, he served as President of the Breast and Skeletal Health Division at Hologic Inc. . During his tenure at Hologic, he led a large, multi-franchise commercial organization and grew one of the company's largest business units—a $1.6+ billion global franchise. He also brings deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed's growth priorities in BCRL, body composition, and heart health. With this experience, Anderson is well-positioned to lead ImpediMed's next phase of growth, expanding sales and distribution across U.S. health systems. Bains will continue in an advisory role through June 30, 2026, to support a smooth leadership transition.
お知らせ • Jan 27ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Oct 24ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025
お知らせ • Sep 19ImpediMed Limited, Annual General Meeting, Nov 18, 2025ImpediMed Limited, Annual General Meeting, Nov 18, 2025.
お知らせ • Jul 16ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025
お知らせ • Apr 17ImpediMed Limited to Report Q3, 2025 Results on Apr 30, 2025ImpediMed Limited announced that they will report Q3, 2025 results on Apr 30, 2025
お知らせ • Jan 28ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025ImpediMed Limited announced that they will report Q2, 2025 results on Jan 31, 2025
お知らせ • Oct 15ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024ImpediMed Limited announced that they will report Q1, 2025 results on Oct 22, 2024
お知らせ • Sep 27ImpediMed Limited, Annual General Meeting, Nov 19, 2024ImpediMed Limited, Annual General Meeting, Nov 19, 2024.
お知らせ • Aug 23ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024ImpediMed Limited announced that they will report fiscal year 2024 results Pre-Market on Aug 29, 2024
お知らせ • Jul 22+ 3 more updatesImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basisAs announced in November 2023, Dr. Parmjot Bains, CEO and Managing Director commenced in their roles in an interim capacity. The Board of ImpediMed Limited confirmed the appointment of Dr. Bains as Chief Executive Officer on an ongoing basis. In the 6-month period in their interim roles, Dr. Bains has implemented a number of significant changes across the business to ensure the Company is in the best position to achieve growth and profitability and ensure all patients at risk of cancer related lymphedema can access ImpediMed's unique technology.
お知らせ • Jun 08ImpediMed Limited Appoints Fiona Bones as A Non-Executive DirectorThe Board of ImpediMed Limited announced the appointment of Ms Fiona Bones as a non-Executive Director of the Company, effective 07 June 2024. Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones is a Fellow of the Association of Chartered Certified Accountants, UK and Ireland and brings global experience in finance, corporate governance, and systems transformation.
お知らせ • Apr 20ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024ImpediMed Limited announced that they will report Q3, 2024 results on Apr 30, 2024
お知らせ • Apr 11ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual MeetingImpediMed announced that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on April 12, 2024. The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period. The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure. Lymphedema, a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk. ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with US payors now providing coverage for over 140 million covered lives. The PREVENT trial is a pivotal study and the largest randomized controlled trial to assess lymphedema prevention. The study enrolled 1,200 patients across 10 trial sites in the US and Australia, involving 13 hospitals, including Vanderbilt University, Mayo Clinic and MD Anderson. The trial was conducted over six and a half years and patients were followed for up to three years, with the primary aim to determine if early intervention in patients with subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy results in a lower rate of lymphedema progression versus the rate when tape measure is used for subclinical detection. The manuscript is published in Lymphatic Research and Biology. The results of the trial demonstrated that patients with early detection with L-Dex™ technology and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years.
お知らせ • Jan 23ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024ImpediMed Limited announced that they will report first half, 2024 results on Feb 27, 2024
お知らせ • Nov 20+ 2 more updatesImpediMed Limited Announces CFO ChangesImpediMed Limited announced leadership and Board changes to drive growth and manage costs. When elected, the Board announced a review of ImpediMed's strategy to ensure it was maximising the potential opportunities to transition to a high growth and profitable business. To date, the Board has considered the Company's operational readiness, approach to execution and cost structure. The review identified a very capable core management team, a distinctive product portfolio and an undeniable opportunity. However, more is needed to deliver robust execution and control costs. Given these challenges and the strong endorsement for change from ImpediMed shareholders at the recent General Meeting, the Board has determined that action now is appropriate. Tim Cruickshank has stepped down as CFO and the Board is discussing transition arrangements with him. Chair McGregor Grant assumes the responsibilities of CFO effective immediately, in an interim capacity and will be an Executive Chairman. The Chair, McGregor Grant will work closely with Dr. Bains as CFO, with a clear focus on managing costs. managing costs. For the last 12 years Mr. Grant was CFO and company Secretary of Nanosonics Limited. As well as leading financial strategy, Mr. Grant played a key role in developing and implementing corporate strategy. He was also responsible for operational functions including IT, legal and facilities management. During Mr. Grant's tenure at Nanosonics revenue grew from $2 million to $166 million. Together, Dr. Bains and Mr. Grant have extensive strategic, sales & marketing, financial and operational experience in high growth MedTech/healthcare businesses and will ensure stability and continuity of the business' operations. The Board recognises the significant talent within the senior management team, and Dr. Bains and Mr. Grant look forward to working closely with them to ensure the entire ImpediMed team remains focused on execution. Dr. Bains and Mr. Grant will also work closely with the management team to more deeply examine the Company's strategic and operational plans and its cost base to maximise the commercial opportunity and deliver value to its shareholders. Dr. Bains and Mr. Grant have been appointed to their roles in an interim capacity, which is expected to be in place for a period of up to six months while they assess the requirements of the business.
お知らせ • Oct 24ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023ImpediMed Limited announced that they will report Q1, 2024 results on Oct 31, 2023
お知らせ • Oct 12ImpediMed Limited, Annual General Meeting, Nov 30, 2023ImpediMed Limited, Annual General Meeting, Nov 30, 2023, at 10:01 E. Australia Standard Time.
お知らせ • Sep 27ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical OfficerImpediMed Limited announced the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023. Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry. Dr. Chen's previous leadership and experience: Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care. Chief of Breast Surgery, University of California Davis Medical Center. Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California. Past President, American Society of Breast Surgeons (ASBrS). Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics. Over 70 publications and 5,000 citations. The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®). Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons. Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business.
お知らせ • Jul 17ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023ImpediMed Limited announced that they will report Q4, 2023 results on Jul 24, 2023
お知らせ • Jul 06ImpediMed Limited Appoints Daniel Sharp as DirectorImpediMed Limited appointed Mr. Daniel Sharp as director, date of appointment is July 1, 2023.
お知らせ • Jan 24ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023ImpediMed Limited announced that they will report Q2, 2023 results on Jan 30, 2023
